NCT00646425 - The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Non-infectious Uveitis

Interventions

DRUG

Basiliximab

40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses

DRUG

Placebo

Placebo to match basiliximab

Trial Locations (6)

New York Eye and Ear Infirmary, New York

Southeast Clinical Research Associates, Belmont

Tauber Eye Center, Kansas City

Vitreoretinal Consultants, Houston

University of Texas Medical Branch, Galveston

Ocular Immunology & Uveitis Foundation, Cambridge